Non Metastatic Breast Cancer clinical trials

Explore recruiting non metastatic breast cancer clinical trials.

Recruiting non metastatic breast cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Non Metastatic Breast Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized, double-blind, vehicle-controlled, multi-centre, parallel-group study to investigate the safety, tolerability, and efficacy of GR1014 cutaneous gel as a topical radioprotector in the prevention of the radiodermatitis occurring with adjuvant radiotherapy for localized breast cancer after lumpectomy

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer: ARIADNE

Sweden, Norway, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase II study of preoperative stereotactic radiation therapy boost combined with short-course immunotherapy (pembrolizumab versus placebo, randomized, double-blind) and standard chemotherapy in patients with newly diagnosed HER2-negative non-metastatic breast cancer with lack of early metabolic response in 18-fluorodeoxyglucoseFDG-PET/CT after 1st chemoterapy cycle

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

UNIRAD : Randomised, double-blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary breast cancer who remain free of disease

Belgium, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Non Metastatic Breast Cancer trials by city

Non Metastatic Breast Cancer in Toronto Non Metastatic Breast Cancer in Vancouver Non Metastatic Breast Cancer in Montreal Non Metastatic Breast Cancer in Calgary Non Metastatic Breast Cancer in Edmonton Non Metastatic Breast Cancer in Ottawa Non Metastatic Breast Cancer in Winnipeg Non Metastatic Breast Cancer in Quebec City Non Metastatic Breast Cancer in Hamilton Non Metastatic Breast Cancer in Kitchener Non Metastatic Breast Cancer in London Non Metastatic Breast Cancer in Halifax Non Metastatic Breast Cancer in New York Non Metastatic Breast Cancer in Los Angeles Non Metastatic Breast Cancer in Chicago Non Metastatic Breast Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease